Opinion|Videos|October 9, 2024
mCRC Treatment Access: IRA Cost Cap Impact and Final Insights
Key Takeaways
- The Inflation Reduction Act's cost cap will reduce financial burdens, enhancing access to oral chemotherapy for metastatic colorectal cancer patients.
- Improved adherence to prescribed therapies is anticipated due to reduced out-of-pocket expenses, potentially leading to better treatment outcomes.
Medical experts discuss how the Inflation Reduction Act’s out-of-pocket prescription drug cost cap, effective in 2025, may impact access to oral chemotherapy options for metastatic colorectal cancer.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Concerning access to these oral chemotherapy options, how do you anticipate the Inflation Reduction Act’s out-of-pocket prescription drug cost cap will impact access to these metastatic colorectal cancer therapies starting in 2025?
Advertisement
Related to this article
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.
Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
2
How Plans, Clinicians Should Handle Gray-Market Retatrutide
3
IVF Beats IUI for Early Live Births in Unexplained Infertility
4
Phase 3 Data Back ALP Normalization as Treatment Goal in PBC
5